Tirocular*coll Fl 10ml 4%

Tirocular*coll Fl 10ml 4%
Regular Price €14.50 Special Price €13.26
-9% Save: €1.24
In stock
icomoon-up
icomoon-down
Manufacturer
ANGELINI
SKU
028165025
Active principle
ACETILCISTEINA
NAME
TIROCULAR 4% EYE DROPS, SOLUTION

PHARMACOTHERAPEUTIC CATEGORY
Ophthalmological drugs.

ACTIVE PRINCIPLES
100 ml of eye drops contain 4 g of acetylcysteine.

EXCIPIENTS
Polyvinyl alcohol, sodium edetate, sodium chloride, potassium chloride, benzalkonium chloride, sodium hydroxide, water for injections.

INDICATIONS
Treatment of ophthalmic disorders due to tear deficit with and without alteration of the mucous component such as: keratoconjunctivitis sicca, corneal affections from impaired lacrimal secretion, keratopathia of different etiology, corneal ulcers.

CONTRAINDICATIONS / SECONDARY EFFECT
Hypersensitivity 'to the active substance or to any of the excipients.

DOSAGE
Instill 1-2 drops into the conjunctival sac 3-4 times a day, according to medical prescription.

STORAGE
The medicinal product does not require any special storage conditions. After opening the package, the eye drops can be used for a period of time not exceeding three weeks. It is recommended to close the bottle immediately after each single application.

WARNINGS
Both preclinical and clinical studies do not reveal the need for particular precautions for the use of the drug. However, it is advisable not to use soft contact lenses during therapy, because they can accumulate the preservative contained in the preparation. Tirocular contains: benzalkonium chloride may cause eye irritation. The bleaching action against soft contact lenses is known, therefore contact must be avoided. The lenses must be removed before instillation of the medicine and must wait at least 15 minutes before putting them back on.

INTERACTIONS
No interactions are known to date in the case of local ocular application.

SIDE EFFECTS
Possible irritation phenomena usually transient and, on hypersensitive subjects, sensitization phenomena that require the interruption of the treatment. Report any suspected adverse reactions via the national reporting system.

PREGNANCY AND BREASTFEEDING
There is no evidence to advise against the use of the drug during pregnancy and lactation.